Status:
WITHDRAWN
A Retrospective Study to Describe Real-World Treatment Patterns and Clinical Outcomes Among Patients With Myelodysplastic Syndromes
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Myelodysplastic Syndromes (MDS)
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to collect real-world data on treatment patterns and clinical outcomes for participants who discontinued Luspatercept or epoetin alfa treatment and discontinued the COMMANDS trial (NCT...
Eligibility Criteria
Inclusion
- Participant was enrolled in and discontinued the COMMANDS trial.
- Participant was treated with either luspatercept or epoetin alfa and discontinued treatment while enrolled in the COMMANDS trial.
- Participant Patient provides informed consent (only where applicable or required by local regulations).
Exclusion
- • There are no exclusion criteria for this study.
Key Trial Info
Start Date :
November 30 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 30 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT06581055
Start Date
November 30 2024
End Date
March 30 2025
Last Update
October 9 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital (NTUH)
Taipei, Taiwan, 10040